scholarly journals BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia

2013 ◽  
Vol 162 (6) ◽  
pp. 848-851 ◽  
Author(s):  
Ayse U. Akarca ◽  
Vishvesh H. Shende ◽  
Alan D. Ramsay ◽  
Tim Diss ◽  
Maria Pane-Foix ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Specific Antibody ◽  
Diagnostic Marker ◽  
Residual Disease ◽  
Braf V600e Mutation ◽  
Hairy Cell Leukaemia ◽  
Braf V600e ◽  
Cell Leukaemia ◽  
Hairy Cell ◽  
Minimal Residual

scholarly journals Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?

2017 ◽  
Vol 183 (1) ◽  
pp. 127-129 ◽  
Author(s):  
Valentín Ortiz-Maldonado ◽  
Neus Villamor ◽  
Tycho Baumann ◽  
Marta Aymerich ◽  
Laura Magnano ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Hairy Cell Leukaemia ◽  
Cell Leukaemia ◽  
Disease Monitoring ◽  
Hairy Cell ◽  
Minimal Residual Disease Monitoring ◽  
Minimal Residual

Rituximab as treatment for minimal residual disease in hairy cell leukaemia

2004 ◽  
Vol 73 (6) ◽  
pp. 412-417 ◽  
Author(s):  
Giulia Cervetti ◽  
Sara Galimberti ◽  
Francesca Andreazzoli ◽  
Rita Fazzi ◽  
Nadia Cecconi ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Hairy Cell Leukaemia ◽  
Cell Leukaemia ◽  
Hairy Cell ◽  
Minimal Residual

scholarly journals Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up

2008 ◽  
Vol 143 (2) ◽  
pp. 296-298 ◽  
Author(s):  
Giulia Cervetti ◽  
Sara Galimberti ◽  
Francesca Andreazzoli ◽  
Rita Fazzi ◽  
Nadia Cecconi ◽  
...  
Keyword(s):  
Minimal Residual Disease ◽  
Residual Disease ◽  
Hairy Cell Leukaemia ◽  
Cell Leukaemia ◽  
Hairy Cell ◽  
Minimal Residual

Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype

2012 ◽  
Vol 34 (4) ◽  
pp. 417-421 ◽  
Author(s):  
S. E. LANGABEER ◽  
D. O’BRIEN ◽  
S. LIPTROT ◽  
C. M. FLYNN ◽  
P. J. HAYDEN ◽  
...  
Keyword(s):  
Braf V600e Mutation ◽  
Hairy Cell Leukaemia ◽  
Braf V600e ◽  
Cell Leukaemia ◽  
Hairy Cell

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2896-2896 ◽  
Author(s):  
Robert J. Kreitman ◽  
Evgeny Arons ◽  
Sapolsky Jeffrey ◽  
Laura Roth ◽  
Hong Zhou ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Flow Cytometry ◽  
Hairy Cell Leukemia ◽  
Residual Disease ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Hairy Cell ◽  
Cell Leukemia ◽  
Specific Primer ◽  
Minimal Residual

Abstract Abstract 2896 Background: Moxetumomab pasudotox is an anti-CD22 recombinant immunotoxin containing truncated Pseudomonas exotoxin which was recently reported to achieve a complete remission rate of 46% in 28 patients with relapsed/refractory hairy cell leukemia (HCL). An additional 20 patients were treated at the highest dose level and are now fully evaluable for response and minimal residual disease (MRD) determinations. RQ-PCR using clone-specific primers and a clone-specific TaqMan probe is capable of detecting one HCL cell in 106normal cells. Recently reported methods to detect the HCL-associated BRAF V600E mutation include pyrosequencing (5–10% sensitivity) and PCR (0.1–0.23% sensitivity). Methods: Moxetumomab pasudotox was administered to 16 patients at 5–40 ug/Kg every other day for 3 doses (QODx3) and to 32 patients at 50 ug/Kg QODx3, via 1–16 (median 4) cycles per patient at 4-week intervals. Complete remission (CR) required resolution of cytopenias and elimination of HCL in the blood and marrow by standard microscopy, but MRD could be present by flow cytometry of blood or bone marrow aspirate (BMA) or immunohistochemistry (IHC) of the bone marrow biopsy (BMBx). Blood and marrow from patients were also tested by PCR using consensus primers. When immunoglobulin (Ig) rearrangements could be cloned, RQ-PCR using clone-specific primer and probe was performed. To detect MRD by the BRAF V600E mutation, BRAF quantitative PCR (BRAF-qPCR) was performed on cDNA samples, using mutant-specific primer, and SYBR-Green detection followed by melting point analysis. MRD testing for BRAF-qPCR, unlike clone-specific RQ-PCR, did not require prior cloning of the Ig rearrangement. Results: All 198 cycles of moxetumomab administered to 48 patients were evaluable for toxicity and response. No dose limiting toxicity was observed, although 2 patients as previously reported had a grade 2 hemolytic uremic syndrome with transient grade 1 platelet and creatinine abnormalities. Of the 48 HCL patients at all dose levels, there were 26 (54%) CRs, with an overall response rate (ORR) of 88%. Of 32 at 50 ug/Kg QODx3, there were 19 (59%) CRs with an ORR of 91%. Of these 19 CRs, 11 (58%) achieved MRD negativity by repeated flow cytometry of both BMA and blood and IHC of BMBx. Flow cytometry of the BMA was the most sensitive conventional test of MRD. Of the 9 CRs at 50 ug/Kg QODx3 evaluable by clone-specific RQ-PCR of blood, 5 negative were also flow-negative, and 4 positive were also flow-positive (p=0.008). BRAF-qPCR on cDNA from limiting dilutions of BRAF V600E+ Colo-205 cells into BRAF wild-type cells achieved consistent detection at 1:105dilution (0.001%). Of 10 flow-negative CRs at 50 ug/Kg QODx3 evaluated by BRAF-qPCR, all 10 (100%) were BRAF-qPCR negative, including 4 which were nonevaluable by RQ-PCR due to inability to clone the Ig rearrangements prior to treatment. Currently 12 (63%) of the 19 CRs at 50 ug/Kg QODx3 are ongoing at 6–47 (median 21) months, including 10 (91%) of 11 MRD-negative vs 2 (25%) of 8 MRD+ CRs (p=0.006). Conclusions: Moxetumomab pasudotox is active in relapsed and refractory HCL and has a safety profile supporting further development for this disease. Retreatment on this trial could not necessarily be extended to achieve MRD-negative BMAs or molecular remission by RQ-PCR using sequence-specific or BRAF primers. However, these tests might be useful in the future to guide retreatment, optimize CR durability and possibly eradicate the HCL clone in selected patients. This summary contains investigator reported data. This study was sponsored by MedImmune, LLC, and supported by NCI's Intramural Research Program and the Hairy Cell Leukemia Research Foundation. Disclosures: Kreitman: NIH: Co-inventor on the NIH patent for Moxetumomab Pasudotox, Co-inventor on the NIH patent for Moxetumomab Pasudotox Patents & Royalties. Off Label Use: Moxetumomab Pasudotox is an experimental agent for CD22+ hematologic malignancies. FitzGerald:NIH: Coinventor on the NIH patent for Moxetumomab Pasudotox, Coinventor on the NIH patent for Moxetumomab Pasudotox Patents & Royalties. Fei:AstraZeneca: Stock, Stock Other; MedImmune, LLC: Employment. Ibrahim:AstraZeneca: Stocks, Stocks Other; MedImmune: Employment. Pastan:NIH: Coinventor on NIH patent for moxetumomab pasudotox, Coinventor on NIH patent for moxetumomab pasudotox Patents & Royalties.

Real-world experience of BRAF V600E mutation testing in hairy cell leukaemia

2020 ◽  
pp. jclinpath-2020-207246
Author(s):  
Stephen E Langabeer ◽  
David O'Brien ◽  
Sarah McCarron ◽  
C Larry Bacon ◽  
Elisabeth Vandenberghe
Keyword(s):  
Real World ◽  
Mutation Testing ◽  
Braf V600e Mutation ◽  
Hairy Cell Leukaemia ◽  
Braf V600e ◽  
Cell Leukaemia ◽  
Hairy Cell

scholarly journals Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia

2011 ◽  
Vol 30 (4) ◽  
pp. 190-193 ◽  
Author(s):  
Mark Ewalt ◽  
Subhadra Nandula ◽  
Adrienne Phillips ◽  
Bachir Alobeid ◽  
Vundavalli V. Murty ◽  
...  
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Braf V600e Mutation ◽  
Hairy Cell Leukaemia ◽  
Frequent Occurrence ◽  
Braf V600e ◽  
Cell Leukaemia ◽  
Hairy Cell ◽  
Intermediate Grade
Sign in / Sign up

Export Citation Format

Share Document